Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 871 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Identical Twins Find Strength in Shared Breast Cancer Battle After Being... November 6, 2019 The UK Government’s spending review: Time to invest in the future... October 20, 2020 Cancer Researchers Bring Tools, Experience to COVID-19 Studies February 12, 2021 Recognising the essential role of clinical research nurses October 13, 2021 Load more HOT NEWS ‘Levelling Up’: What should it mean for cancer? FDA Approves Lenvatinib Plus Pembrolizumab for Advanced Renal Cell Carcinoma American tobacco company Philip Morris International offers £1bn for UK pharma... EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR...
